Vivantes Netzwerk fuer Gesundheit GmbH

At Vivantes Netzwerk fuer Gesundheit GmbH in Berlin, a major focus is on hematologic cancers, especially acute myeloid leukemia, multiple myeloma, and several forms of lymphoma. The trials in this area are designed to test new treatment strategies, improve disease control, and extend survival for patients with difficult-to-treat blood cancers.

• Acute myeloid leukemia and myelodysplastic syndromes, with studies aimed at improving treatment effectiveness and long-term outcomes
• Multiple myeloma, including research on combination approaches and maintenance treatment to deepen response
• Diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and other non-Hodgkin lymphomas, with a focus on newer immunotherapy-based options

The site’s work in oncology includes both newly diagnosed and relapsed disease, reflecting a broad effort to refine care across the full course of blood cancer treatment.

Another prominent area is lung cancer research, covering non-small cell lung cancer, small cell lung cancer, and other advanced respiratory malignancies. These studies mainly evaluate new therapies and treatment combinations intended to improve tumor control, delay progression, and support better outcomes after standard therapy.

• Non-small cell lung cancer, including locally advanced, metastatic, and resectable disease
• Small cell lung cancer, with trials focused on patients who still need better treatment options after initial therapy
• Progressive fibrosing interstitial lung disease and idiopathic pulmonary fibrosis, where research aims to slow disease worsening

The Department of Innere Medizin - Hämatologie und Onkologie is involved in studies that span both cancer and chronic lung disease, showing a strong interest in conditions with major unmet medical need.

This research portfolio also includes a wide range of solid tumors, particularly breast cancer, colorectal cancer, gastric cancer, and prostate cancer. The trials are generally aimed at testing new targeted or immune-based treatments, improving postoperative care, and finding better ways to control advanced or metastatic disease.

• Breast cancer, including hormone receptor-positive, HER2-negative, HER2-low, and triple-negative disease
• Colorectal and rectal cancer, with studies exploring adjuvant treatment and recurrence prevention
• Prostate cancer, including high-risk and metastatic forms, with research focused on delaying progression and improving disease control

Across these tumor types, the site is contributing to research on both treatment effectiveness and personalized oncology, helping identify which patients may benefit most from newer approaches.

Vivantes Netzwerk fuer Gesundheit GmbH is also active in studies of head and neck cancer, bladder cancer, and other advanced solid tumors. These trials commonly examine new perioperative or post-treatment strategies, with the goal of reducing recurrence and improving survival after standard care.

• Head and neck squamous cell carcinoma, including locally advanced and recurrent disease
• Muscle-invasive bladder cancer, where research is focused on improving outcomes around surgery
• Broader studies in recurrent or metastatic solid tumors, supporting development of new cancer therapies across multiple tumor types

This mix of studies shows a broad commitment to clinical oncology, with attention to both common and harder-to-treat cancers.

The site has an important neurology program centered on epilepsy, status epilepticus, and related seizure disorders. These trials aim to improve seizure control, evaluate better rescue or maintenance treatments, and support care for patients whose seizures remain difficult to manage.

• Focal-onset seizures and refractory focal epilepsy, with research focused on reducing seizure frequency
• Primary generalized tonic-clonic seizures and idiopathic generalized epilepsy, where studies seek better long-term control
• Status epilepticus in older adults, with work aimed at improving emergency treatment effectiveness

These studies reflect a strong interest in brain and nervous system disorders that can significantly affect independence and quality of life.

Clinical trials at the Berlin site also address cardiovascular disease and selected bleeding and clotting disorders. The research includes stroke prevention, heart attack recovery, and inherited coagulation conditions, with the overall purpose of improving prevention and reducing serious complications.

• Acute ischemic stroke, transient ischemic attack, and atrial fibrillation-related stroke risk
• Acute myocardial infarction and recurrent heart attack prevention
• Hemophilia A, hemophilia B, von Willebrand disease, and congenital antithrombin deficiency, with studies focused on safer long-term management

These trials combine cardiology and hematology, highlighting the site’s role in research on both vascular events and inherited blood disorders.

The remaining trial portfolio includes mental health, respiratory disease, and diagnostic research. Here, the aim is often to better understand symptom control, prevent relapse, or improve the way disease is detected and followed over time.

• Major depressive disorder and borderline personality disorder, with studies exploring relapse prevention and symptom improvement
• Respiratory tract diseases such as bronchiectasis and severe viral lung infections, where the goal is to improve clinical management
• Diagnostic and imaging-related research, including work on contrast agent exposure and broader evaluation methods

Although smaller in volume than the oncology program, these studies add important breadth to the research activity at Vivantes Netzwerk fuer Gesundheit GmbH.